Study to Evaluate Letrozole, Pyrotinib Combined With SHR6390 in Patients With HR+/HER2+ Relapsed/Metastatic Breast Cancer

Condition:   Breast Cancer Interventions:   Drug: Letrozole;   Drug: Pyrotinib;   Drug: SHR6390 Sponsors:   Fudan University;   Jiangsu HengRui Medicine Co., Ltd. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials